These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 35866165)

  • 1. Protein scaffolds: antibody alternatives for cancer diagnosis and therapy.
    Luo R; Liu H; Cheng Z
    RSC Chem Biol; 2022 Jul; 3(7):830-847. PubMed ID: 35866165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering of Affibody Molecules.
    Ståhl S; Lindberg H; Hjelm LC; Löfblom J; Dahlsson Leitao C
    Cold Spring Harb Protoc; 2024 Nov; 2024(11):pdb.top107760. PubMed ID: 37491082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in the development of novel protein scaffolds based therapeutics.
    Azhar A; Ahmad E; Zia Q; Rauf MA; Owais M; Ashraf GM
    Int J Biol Macromol; 2017 Sep; 102():630-641. PubMed ID: 28412342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineered Protein Scaffolds as Next-Generation Therapeutics.
    Gebauer M; Skerra A
    Annu Rev Pharmacol Toxicol; 2020 Jan; 60():391-415. PubMed ID: 31914898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro-engineered non-antibody protein therapeutics.
    Simeon R; Chen Z
    Protein Cell; 2018 Jan; 9(1):3-14. PubMed ID: 28271446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineering of binding functions into proteins.
    Gebauer M; Skerra A
    Curr Opin Biotechnol; 2019 Dec; 60():230-241. PubMed ID: 31207556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DARPins and other repeat protein scaffolds: advances in engineering and applications.
    Boersma YL; Plückthun A
    Curr Opin Biotechnol; 2011 Dec; 22(6):849-57. PubMed ID: 21715155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomedical Applications of a Novel Class of High-Affinity Peptides.
    Saw PE; Xu X; Kim S; Jon S
    Acc Chem Res; 2021 Sep; 54(18):3576-3592. PubMed ID: 34406761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel, stable, helical scaffold as an alternative binder - construction of phage display libraries.
    Cyranka-Czaja A; Otlewski J
    Acta Biochim Pol; 2012; 59(3):383-90. PubMed ID: 23032749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clustering of disulfide-rich peptides provides scaffolds for hit discovery by phage display: application to interleukin-23.
    Barkan DT; Cheng XL; Celino H; Tran TT; Bhandari A; Craik CS; Sali A; Smythe ML
    BMC Bioinformatics; 2016 Nov; 17(1):481. PubMed ID: 27881076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of novel protein scaffolds as alternatives to whole antibodies for imaging and therapy: status on discovery research and clinical validation.
    Wurch T; Lowe P; Caussanel V; Bes C; Beck A; Corvaia N
    Curr Pharm Biotechnol; 2008 Dec; 9(6):502-9. PubMed ID: 19075688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticalin® proteins: from bench to bedside.
    Deuschle FC; Ilyukhina E; Skerra A
    Expert Opin Biol Ther; 2021 Apr; 21(4):509-518. PubMed ID: 33074019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient selection of DARPins with sub-nanomolar affinities using SRP phage display.
    Steiner D; Forrer P; Plückthun A
    J Mol Biol; 2008 Oct; 382(5):1211-27. PubMed ID: 18706916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specificity grafting of human antibody frameworks selected from a phage display library: generation of a highly stable humanized anti-CD22 single-chain Fv fragment.
    Krauss J; Arndt MA; Martin AC; Liu H; Rybak SM
    Protein Eng; 2003 Oct; 16(10):753-9. PubMed ID: 14600205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An overview on display systems (phage, bacterial, and yeast display) for production of anticancer antibodies; advantages and disadvantages.
    Mahdavi SZB; Oroojalian F; Eyvazi S; Hejazi M; Baradaran B; Pouladi N; Tohidkia MR; Mokhtarzadeh A; Muyldermans S
    Int J Biol Macromol; 2022 May; 208():421-442. PubMed ID: 35339499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxin Neutralization Using Alternative Binding Proteins.
    Jenkins TP; Fryer T; Dehli RI; Jürgensen JA; Fuglsang-Madsen A; Føns S; Laustsen AH
    Toxins (Basel); 2019 Jan; 11(1):. PubMed ID: 30658491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Towards multi-dynamic mechano-biological optimization of 3D-printed scaffolds to foster bone regeneration.
    Metz C; Duda GN; Checa S
    Acta Biomater; 2020 Jan; 101():117-127. PubMed ID: 31669697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stability-Diversity Tradeoffs Impose Fundamental Constraints on Selection of Synthetic Human V
    Henry KA; Kim DY; Kandalaft H; Lowden MJ; Yang Q; Schrag JD; Hussack G; MacKenzie CR; Tanha J
    Front Immunol; 2017; 8():1759. PubMed ID: 29375542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oligopeptide m13 phage display in pathogen research.
    Kügler J; Zantow J; Meyer T; Hust M
    Viruses; 2013 Oct; 5(10):2531-45. PubMed ID: 24136040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of an interloop disulfide bond in high-affinity antibody mimics based on fibronectin type III domain and selected by yeast surface display: molecular convergence with single-domain camelid and shark antibodies.
    Lipovsek D; Lippow SM; Hackel BJ; Gregson MW; Cheng P; Kapila A; Wittrup KD
    J Mol Biol; 2007 May; 368(4):1024-41. PubMed ID: 17382960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.